Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT

References

• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–10. doi:10.1016/S0065-2776(06)90008-X. PMID: 16730267.
   PubMed Web of Science ®Google Scholar
• Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895. doi:10.3389/fimmu.2021.699895. PMID: 34367161.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001. PMID: 27192565.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. doi:10.1038/ni.1674. PMID: 19011627.
   PubMed Web of Science ®Google Scholar
• Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol. 2009;39(3):695–703. doi:10.1002/eji.200839116. PMID: 19197944.
   PubMed Web of Science ®Google Scholar
• Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009;58(9):1517–26. doi:10.1007/s00262-009-0682-y. PMID: 19259667.
   PubMed Web of Science ®Google Scholar
• Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P, Denis MG. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49(2):236–40. doi:10.1136/gut.49.2.236. PMID: 11454801.
   PubMed Web of Science ®Google Scholar
• Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Satoh N, Ogita H, Takai Y, et al. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 2010;101(5):1326–30. doi:10.1111/j.1349-7006.2010.01530.x. PMID: 20331633.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Gully BS, Rossjohn J, Berry R. Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J Biol Chem. 2017;292:11413–22. doi:10.1074/jbc.M117.786483. PMID: 28515320.
   PubMed Web of Science ®Google Scholar
• Saha S, Sparkes A, Matus EI, Lee P, Gariepy J. The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity. Sci Rep. 2023;13(1):4609. doi:10.1038/s41598-023-30999-w. PMID: 36944702.
   PubMed Web of Science ®Google Scholar
• Lee PS, Chau B, Barman I, Bee C, Jashnani A, Hogan JM, Aguilar B, Dollinger G, Rajpal A, Strop P. Antibody blockade of CD96 by distinct molecular mechanisms. MAbs. 2021;13(1):1979800. doi:10.1080/19420862.2021.1979800. PMID: 34595996.
   PubMed Web of Science ®Google Scholar
• Harrison OJ, Vendome J, Brasch J, Jin X, Hong S, Katsamba PS, Ahlsen G, Troyanovsky RB, Troyanovsky SM, Honig B, et al. Nectin ectodomain structures reveal a canonical adhesive interface. Nature Structural & Molecular Biology. 2012;19(9):906–15. doi:10.1038/nsmb.2366. PMID: 22902367.
   PubMed Web of Science ®Google Scholar
• Samanta D, Guo H, Rubinstein R, Ramagopal UA, Almo SC. Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2. Mol Immunol. 2017;81:151–59. doi:10.1016/j.molimm.2016.12.003. PMID: 27978489.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Watson GM, Fu Z, Rossjohn J, Berry R. Structural basis for CD96 immune receptor recognition of nectin-like Protein-5, CD155. Structure. 2019;27(2):219–28.e3. doi:10.1016/j.str.2018.10.023. PMID: 30528596.
   PubMed Web of Science ®Google Scholar
• Liu J, Qian X, Chen Z, Xu X, Gao F, Zhang S, Zhang R, Qi J, Gao GF, Yan J. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J Immunol. 2012;188(11):5511–20. doi:10.4049/jimmunol.1200324. PMID: 22547693.
   PubMed Web of Science ®Google Scholar
• Wang H, Qi J, Zhang S, Li Y, Tan S, Gao GF. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. Proc Natl Acad Sci U S A. 2019;116:988–96. doi:10.1073/pnas.1815716116. PMID: 30591568.
   PubMed Web of Science ®Google Scholar
• Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL, Grogan JL. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A. 2012;109(14):5399–404. doi:10.1073/pnas.1120606109. PMID: 22421438.
   PubMed Web of Science ®Google Scholar
• White M, Kumar S, Chan C, Liang S, Stapleton L, Drake A, Gozlan Y, Vaknin I, Sameah-Greenwald S, Dassa L, et al. Inventor; anti-TIGIT Antibodies, Anti-PVRIG antibodies and combinations there of. 2018. WO 2018/033798 A1.
   Google Scholar
• Jeong BS, Nam H, Lee J, Park HY, Cho KJ, Sheen JH, Song E, Oh M, Lee S, Choi H, et al. Structural and functional characterization of a monoclonal antibody blocking TIGIT. MAbs. 2022;14(1):2013750. doi:10.1080/19420862.2021.2013750. PMID: 35090381.
   PubMed Web of Science ®Google Scholar
• Grogan JL, Johnston RJ, Wu Y, Liang W, Lupardus P, Yadav M, Seshasayee D, Hazen M. Inventor; Anti-TIGIT antibodies and methods of use. 2017. WO2017053748A2.
   Google Scholar
• Williams S, Laface D, Fayadat-Dilman L, Raghunathan R, Liang L, Seghezzi W. Inventor; anti-TIGIT antibodies. 2016. WO/2016/028656.
   Google Scholar
• Tso Y, Tsurushita N, Duramad O. Inventor; ANTIBODIES to TIGIT. 2017. WO/2017/152088A1.
   Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, et al. TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125(5):2046–58. doi:10.1172/JCI80445. PMID: 25866972.
   PubMed Web of Science ®Google Scholar
• Jin HS, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54(1):2–11. PMID: 33298247. https://www.ncbi.nlm.nih.gov/pubmed/33298247.
   PubMed Web of Science ®Google Scholar
• van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185(3):393–404. doi:10.1084/jem.185.3.393.
   PubMed Web of Science ®Google Scholar
• Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited. Immunity. 2002;17(2):201–10. doi:10.1016/s1074-7613(02)00362-x. PMID: 12196291.
   PubMed Web of Science ®Google Scholar
• Chen X, Song X, Li K, Zhang T. FcgammaR-Binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol. 2019;10:292. doi:10.3389/fimmu.2019.00292. PMID: 30863404.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:10.1007/s13238-017-0473-8. PMID: 28986820.
   PubMed Web of Science ®Google Scholar
• Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT/CD226 axis regulates anti-tumor Immunity. Pharmaceuticals (Basel). 2021;14(3):200. doi:10.3390/ph14030200. PMID: 33670993.
   PubMedGoogle Scholar
• Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr. 2011;67(4):293–302. doi:10.1107/S0907444911007773. PMID: 21460447.
   PubMedGoogle Scholar
• Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010;66(2):125–32. doi:10.1107/S0907444909047337. PMID: 20124692.
   PubMedGoogle Scholar
• Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2006;62(1):72–82. doi:10.1107/S0907444905036693. PMID: 16369096.
   PubMedGoogle Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67(4):235–42. doi:10.1107/S0907444910045749. PMID: 21460441.
   PubMed Web of Science ®Google Scholar
• Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(1):12–21. doi:10.1107/S0907444909042073. PMID: 20057044.
   PubMedGoogle Scholar